A therapy that would once have been considered a feat of science fiction has reversed aggressive and incurable blood cancers in some patients, doctors report. The treatment involves precisely editing the DNA in white blood cells to transform them into a cancer-fighting living drug. The first girl to be treated, whose story we reported in 2022, is still free of the disease and now plans to become a cancer scientist. Now eight more children and two adults with T-cell acute lymphoblastic leukaemia have been treated, with almost two thirds (64%) of patients in remission. T-cells are supposed to be the body's guardians - seeking out and destroying threats - but in this form of leukaemia, they grow out of control.

Artificial Intelligence (AI) is transforming the world of hematology and hematopathology. In a recent update on AI-based hematopathology, Scopio Labs has announced the launch of the Full-Field Bone Marrow AspirateTM (FF-BMA) Application. Currently, Scorpio Labs is providing Full-Field Cell Morphology imaging and AI-powered analysis platforms to support laboratory professionals in the detection of cancers, anemia, infections, and other blood-related disease. This AI-based hematopathology platform is the first to enable a complete digital workflow for bone marrow aspirate scanning and analysis. Scopio's high resolution Full-Field imaging and AI-driven Decision Support System brings a much-desired digital transformation to hematopathology.

GNS Healthcare on Thursday launched an artificial intelligence platform that acts as a virtual patient, allowing drugmakers and academic centers to experiment with drugs in the virtual world before treating patients in clinical trials. The platform, called Gemini, is made to simulate individuals with a deadly type of blood cancer called multiple myeloma. About 32,270 people in the U.S. will be diagnosed with the disease in 2020, according to the American Cancer Society.

Precision oncology firm Notable Labs is launching its first self-sponsored clinical trial, designed from the ground up to help validate its cancer patient matching platform over the long term. The observational study--which also represents the company's largest trial to date--aims to enroll up to 1,000 participants with a variety of blood cancers and will follow them for at least one year as they receive physician-led standard-of-care therapies at different sites across the U.S. and Canada. Separately, Notable's phenotypic and artificial intelligence-powered platform will be tested against multiple patient samples collected over time to provide a longitudinal view of its predictive value based on cancer mutations, drug responses and the outcomes of each participant. It will also search for patterns useful in the development of new treatments. The company combines AI approaches with automated lab processes to determine which drugs or combinations will be most effective for specific cancers.

Washington: Tracking down acute myeloid leukaemia (AML), researchers have proved that artificial intelligence can detect forms of blood cancer. The study was conducted by the researchers of the German Center for Neurodegenerative Diseases (DZNE) and was published in the recent edition of the iScience journal. The approach used by researchers revolved around the gene activity analysis of cells that are present in the blood. This approach could support conventional diagnostics and accelerate therapy of the disease. "Some studies have been carried out on this topic and the results are available through. Thus, there is an enormous data pool. We have collected virtually everything that is currently available," said Professor Joachim Schultze who led the group of researchers of the study.

Artificial Intelligence can help detect one of the most common forms of blood cancer - acute myeloid leukaemia (AML) - with high reliability, new research has found. Their approach, based on the analysis of the gene activity of cells found in the blood, could support conventional diagnostics and possibly accelerate the beginning of therapy, said the study published in the journal iScience. In the early stages the symptoms of AML can resemble those of a bad cold. However, AML is a life-threatening disease that should be treated as quickly as possible. "With a blood test, as it seems possible on the basis of our study, it is conceivable that the family doctor would already clarify a suspicion of AML," said Joachim Schultze, a research group leader at the German Center for Neurodegenerative Diseases (DZNE).